|
Oncology Market Leaders – Analyses and Outlook – 2010-2025Übersetzung: Onkologie Marktfuehrer - Analysen und Perspektiven 2010-2025
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
This report will provide you with the following benefits, in particular: 186 seiten | |||||||||||
| Inhalt der Studie: |
Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WH.....
Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, especially in biomolecular medicine. Current treatments are better-tolerated, more- effective and more-commercially-successful than ever before, our latest report shows. The aging of populations, lifestyle changes in the developing world, together with significant advances in pharmacotherapy and diagnostics, will drive the cancer treatments market from 2010 onwards. Increasing disease prevalence and a strong R&D pipeline make the anti-cancer sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report, Oncology Market Leaders – Analyses and Outlook – 2010-2025, explains why and to what extent, revealing where the most-exciting and lucrative developments will lie from 2010 onwards. There, you will find detailed sales predictions and supporting discussions. This report examines commercial prospects for the following therapy types in particular: • Traditional cytotoxic chemotherapies • Hormone therapies • Immunotherapies • Novel antineoplastic drugs. What new agents are likely to enter the cancer treatments market from 2010 onwards? Do they hold the potential to dominate this market area? What issues are shaping the anti-cancer market? Where will the best commercial opportunities lie from 2010 onwards? What are the most-crucial drivers and restraints in the cancer treatments sector? This report will provide you with the information that you need to understand current trends and future commercial possibilities there. In particular, Oncology Market Leaders – Analyses and Outlook – 2010-2025 analyses sales prospects for the following products: • Avastin • MabThera • Herceptin • Glivec/Gleevec • Taxotere • Eloxatin • Arimidex • Gemzar • Erbitux • Alimta Also included is analysis of the leading companies in the anti-cancer drug sector. There, we discuss major portfolio and pipeline products, as well as their future therapeutic and commercial prospects. Comprehensive analysis of the oncology market sector Oncology Market Leaders – Analyses and Outlook – 2010-2025 examines the cancer treatments market critically, through a comprehensive review of information sources. We harness both primary and secondary research. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including SWOT analyses. The report contains over 140 tables and figures, as well as three full interviews with relevant authorities. You will discover a comprehensive market- and industry-centred study, one with detailed analyses and informed opinion to benefit your work. Nobody with an interest in the anti-cancer drug market should overlook this new study. We predict that total revenues will increase there, with the anti-cancer drug segment contributing increasingly to the success of the pharmaceutical and biotechnology industries. With expanding patient populations, technological advances and strong R&D pipelines, the anti-cancer drug sector holds particularly high commercial potential. Do you want to harness those opportunities? You can stay ahead by ordering this report today. Report Highlights Companies Listed: Abraxis BioScience Inc. Access Pharmaceuticals Inc. Actavis Almac Group Ltd American Cancer Society Apotex AstraZeneca Bayer Healthcare Biogen Idec BiPar Science Inc. Bristol-Myers Squibb British National Formulary Cancer Research UK Cell Therapeutics Inc. Committee for Medicinal Products for Human Use (CHMP) Chugai Pharmaceuticals CytImmune Sciences Dendreon Corporation Dr. Reddy’s Laboratories Eli Lilly European Medicines Agency (EMEA) Food and Drug Administration (FDA) Genentech Genta Inc. GlaxoSmithKline Hospira Inc. ImClone Systems International Agency for Research on Cancer (IARC) Johnson & Johnson Merck & Co Merck KGaA Merck Serono National Cancer Institute (NCI) National Health Service (NHS) National Institute for Clinical Excellence (NICE) National Institutes of Health (NIH) Novartis Pfizer Regeneron Pharmaceuticals Inc. Roche Sandoz Sanofi-Aventis Schering Plough Serono Stada Arzneimittel AG Teva Pharmaceutical Industries US Preventive Services Task Force (USPSTF) Ventana Medical Systems Vernalis World Health Organisation (WHO) Wyeth Pharmaceuticals Yeda Research and Development Company Ltd. Zenyaku Kogyo Co. Ltd. [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 2. The Global Burden of Cancer 2.1 The Impact of Cancer 2.2 Incidence: Which Cancers Are The Most Commonly Diagnosed? 2.3 Mortality: Which Cancers Kill the Most People? 2.3.1 The Developed World 2.3.2 The Developing World 3. The Physiology of Cancer and the Pharmacology of Treatments 3.1 Uncontrolled Growth 3.1.1 Oncogenes and Tumour Suppressor Genes 3.1.2 Immortality 3.1.3 Apoptosis 3.1.4 Angiogenesis 3.1.5 Dedifferentiation 3.1.6 Invasiveness and Metastasis 3.2 Treating Tumours 3.3 Chemotherapy 3.4 Traditional Antineoplastics 3.4.1 Alkylating Agents 3.4.1.1 Traditional Alkylating Agents 3.4.1.2 Platinum Compounds 3.4.2 Antimetabolites 3.4.3 Plant Derivatives 3.4.4 Cytotoxic Antibiotics 3.4.5 Adjuvant Therapies 3.5 Novel Antineoplastics 3.5.1 Monoclonal Antibodies 3.5.2 Kinase Receptor Antagonists 3.5.3 Other Novel Antineoplastics 3.6 Hormone Therapies 3.7 Immunotherapies 4. The Global Cancer Drug Market, 2010-2025 4.1 The Scope of this Report 4.1.1 Drugs Excluded from this Report 4.2 The Worldwide Oncology Market 4.3 Oncology Revenues by Geographical Area 4.4 Leading Markets and Emerging Markets 4.4.1 The Seven Leading Markets 4.4.2 The Five Emerging Markets 4.5 Oncology Market Break-Down by Category 4.5.1 Oncology Market Break-Down by Mechanism of Action 4.6 Oncology Market Sales Forecast, 2010-2025 4.7 Traditional Antineoplastics 4.7.1 Sales Forecast for Traditional Antineoplastics, 2010-2025 4.8 Novel Antineoplastics 4.8.1 Sales Forecast for Novel Antineoplastics, 2010-2025 4.9 Hormone Therapies 4.9.1 Sales Forecast for Hormone Therapies, 2010-2025 4.10 Immunotherapies 4.10.1 Sales Forecast for Immunotherapy Market, 2010-2025 4.11 How Market Shares of Each Category will Change, 2010-2025 5. The Market Leaders: Top Ten Anti-Cancer Drugs 5.1 The Costs of The Top Ten Drugs 5.2 Important Notes on the Top Ten Drugs 5.3 Avastin (bevacizumab) - Roche 5.3.1 Overview 5.3.2 Recent Performance 5.3.3 Forecast 5.3.4 Comment 5.4 MabThera (rituxamab) – Roche 5.4.1 Overview 5.4.2 Recent Performance 5.4.3 Forecast 5.4.4 Comment 5.5 Herceptin (trastuzumab) - Roche 5.5.1 Overview 5.5.2 Recent Performance 5.5.3 Forecast 5.5.4 Comment 5.6 Glivec/Gleevec (imatinib) - Novartis 5.6.1 Overview 5.6.2 Recent Performance 5.6.3 Forecast 5.6.4 Comment 5.7 Taxotere (docetaxel) - Sanofi-Aventis 5.7.1 Overview 5.7.2 Recent Performance 5.7.3 Forecast 5.7.4 Comment 5.8 Eloxatin (oxaliplatin) - Sanofi-Aventis 5.8.1 Overview 5.8.2 Recent Performance 5.8.3 Forecast 5.8.4 Comment 5.9 Arimidex (anastrazole) - AstraZeneca 5.9.1 Overview 5.9.2 Recent Performance 5.9.3 Forecast 5.9.4 Comment 5.10 Gemzar (gemcitabine) - Eli Lilly 5.10.1 Overview 5.10.2 Recent Performance 5.10.3 Forecast 5.10.4 Comment 5.11 Erbitux (cetuximab) - Eli Lilly/BMS/Merck KGaA 5.11.1 Overview 5.11.2 Recent Performance 5.11.3 Forecast 5.11.4 Comment 5.12 Alimta (pemetrexed) - Eli Lilly 5.12.1 Overview 5.12.2 Recent Performance 5.12.3 Forecast 5.12.4 Comment 6. The Market Leaders: The Top Five Companies 6.1 Roche 6.1.1 Key Oncology Products 6.1.2 Pipeline 6.1.3 Comment 6.2 Novartis 6.2.1 Key Oncology Products 6.2.2 Pipeline 6.3 Sanofi-Aventis 6.3.1 Key Oncology Products 6.3.2 Pipeline 6.3.3 Comment 6.4 AstraZeneca 6.4.1 Key Oncology Products 6.4.2 Pipeline 6.4.3 Comment 6.5 Eli Lilly 6.5.1 Key Oncology Products 6.5.2 Pipeline 6.5.3 Comment 7. Major Issues Shaping the Oncology Drugs Market 7.1 SWOT Analysis of the Oncology Market, 2010-2025 7.2 The Main Factors Driving the Growth of the Oncology Market 7.2.1 High Profile 7.2.2 The Price of Drugs 7.2.3 Patient Power 7.2.4 Incremental Improvements in Treatment in the Absence of a Complete Cure 7.2.5 Effect of Generics 7.2.6 Drug Development 7.2.7 Live Licensing 7.2.8 Increase in Cancer Incidence 7.2.8.1 Aging Populations 7.2.8.2 Smoking 7.2.8.3 Dietary Trends in Industrialised Nations 7.2.8.4 Obesity 7.2.9 The Developing World 7.2.9.1 Industrialisation 7.2.9.2 The Emerging Middle Class 7.2.9.3 Diseases of Affluence 7.2.9.4 Prioritisation by Individuals 7.2.9.5 Informed Populations 7.2.9.6 Prioritisation by Governments 7.2.10 Screening and Diagnosis 7.2.11 Understanding Cancer Physiology 7.2.12 Personalised Medicine 7.2.13 Drug Delivery Systems 7.2.14 Nanotechnology 7.2.14.1 Diagnostics 7.2.14.2 Drug Delivery 7.2.14.3 Surgery 7.2.15 Off-Label Prescriptions 7.3 The Main Factors Restraining the Growth of the Oncology Market 7.3.1 The Cost-Effectiveness Debate 7.3.2 Governmental Payers and the Maximum Cost of Drugs 7.3.2.1 Healthcare Reform in the US 7.3.2.2 The Implications of Price-Capping Cancer Drugs 7.3.2.3 A Two-Tier System? 7.3.3 Pricing-Out the Developing World? 7.3.4 Risk Sharing 7.3.5 Research Bias and 'Me-Too' Drugs? 7.3.6 Public Health Initiatives 7.3.7 Efficacy, Toxicity and Alternative Treatments 7.3.8 The Patent Cliff 7.4 Unmet Needs in the Oncology Market 7.4.1 Tolerable Drugs 7.4.2 Convenient Drugs 7.4.3 Shift in Perceptions for the Goal of Cancer Treatment 7.4.4 Tumour Resistance 7.4.5 Greater Use of Pharmacogenomics 7.4.6 A Comprehensive Database of Biomarkers 7.4.7 Rigorous Endpoints in Clinical Trials 7.4.8 Is There a Research Bias? 7.4.9 Early Detection 7.4.10 Over-Treatment and Active Surveillance 7.4.11 Access to Treatment in Developing Nations 8. Interviews with Relevant Experts 8.1 Dr Hilmar Warenius 8.1.1 Current Work 8.1.2 Heterogeneity of Tumours 8.1.3 Normal Gene Products 8.1.4 Diagnostics and Pharmacogenomics 8.1.5 The Efficacy of New Treatments 8.1.6 Targeted Antineoplastics and Traditional Chemotherapy 8.1.7 Vaccines and Screening 8.1.8 Therapeutic Vaccines 8.1.9 Conclusions 8.2 Dr Howard McLeod 8.2.1 The Importance of Pharmacogenomics 8.2.2 Drivers 8.2.3 Restraints 8.2.4 Effective Drugs Missed by Clinical Trials 8.2.5 Major Breakthroughs 8.2.6 One Size Fits All? 8.2.7 Blood Tests 8.2.8 Ethics 8.3 Dr Lawrence Tamarkin 8.3.1 Impact of Nanotechnology on Oncology 8.3.1.1 Cancer as a Lifetime Chronic Condition 8.3.1.2 The Developing World 8.3.2 Timeframes 8.3.3 Difficulties and Limits 8.3.4 Further Applications 8.3.5 Drivers 8.3.6 Public Relations 9. Conclusions 9.1 Cancer Will Become an Even More Important Healthcare Priority, Especially in the Developing World 9.2 Of the Wide Range of Oncology Treatments Available, Novel Therapies are Most Important 9.3 The Global Oncology Market Will Continue to Achieve Strong Growth 9.4 The US Oncology Market Leads 9.5 In Terms of Revenue, Monoclonal Antibodies Dominate the Oncology Market 9.6 The Top Ten Drugs Owe Their Successes to Different Factors 9.7 Will Roche Continue to Lead the Global Anti-Cancer Drugs Market? 9.8 The Most Important Drivers of the Oncology Market 9.9 The Greatest Restraint on the Oncology Market 9.10 The Greatest Unmet Need in Cancer Treatment and Concluding Remarks [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 Leading Causes of Death Worldwide, 2008 Table 2.2 Cancer Incidence and Mortality, 2008-2025 Table 2.3 The Ten Most Common Cancers by Incidence, 2008 Table 2.4 Five-Year Survival Rates of Nine Cancers in the UK Table 3.1 Categories of Oncology Drug, 2010 Table 3.2 Common Side-Effects of Traditional Antineoplastic Chemotherapy Table 4.1 Global Pharmaceutical Sales by Disease Area, 2009 Table 4.2 Oncology Drug Sales by Region, 2009 Table 4.3 Comparison of the Oncology Revenues of the Seven Leading Markets and Five Emerging Markets, 2009 Table 4.4 Comparison of the Oncology Revenues of the US, Six Other Leading Markets and Five Emerging Market Groups, 2009 Table 4.5 The Seven Leading National Markets: Oncology Sales, 2009 Table 4.6 The Five Emerging Markets: Oncology Sales, 2009 Table 4.7 Oncology Market by Therapy Type: World Sales, 2009 Table 4.8 Oncology Market Break-Down by Mechanism of Action: World Sales and Market Shares, 2009 Table 4.9 Oncology Drug Market: World Sales Forecast, 2010-2025 Table 4.10 Oncology R&D Pipelines by Category, 2009 Table 4.11 Traditional Antineoplastics: World Sales and Market Shares by Category, 2009 Table 4.12 Traditional Antineoplastics Market: World Sales Forecast, 2010-2025 Table 4.13 Novel Antineoplastics Market Categories: World Sales and Market Shares, 2009 Table 4.14 Novel Antineoplastics Market: World Sales Forecast, 2010-2025 Table 4.15 Hormone Therapy Subtypes: World Sales and Market Shares, 2009 Table 4.16 Hormone Therapy Market: World Sales Forecast, 2010-2025 Table 4.17 Immunotherapy Subtypes: World Sales, 2009 Table 4.18 Immunotherapy Market: World Sales Forecast, 2010-2025 Table 4.19 Overall Categories: Market Shares, 2010-2025 Table 5.1 The Top Ten Oncology Drugs Ranked by Total World Sales, 2009 Table 5.2 Costs of the Top Ten Anti-Cancer Drugs in the UK, 2009 Table 5.3 Avastin Sales Information, 2009 Table 5.4 Avastin Approvals, 2009 Table 5.5 Potential Indications for Avastin, 2009 Table 5.6 Avastin World Sales, 2005-2009 Table 5.7 Avastin World Sales Forecast, 2010-2025 Table 5.8 SWOT Analysis for Avastin, 2010 Table 5.9 MabThera Sales Information, 2009 Table 5.10 MabThera Approvals, 2009 Table 5.11 MabThera World Sales 2005-2009 Table 5.12 MabThera World Sales Forecast, 2010-2025 Table 5.13 SWOT Analysis for MabThera, 2010 Table 5.14 Herceptin Sales Information, 2009 Table 5.15 Potential Indications for Herceptin, 2009 Table 5.16 Herceptin World Sales, 2005-2009 Table 5.17 Herceptin World Sales Forecast, 2010-2025 Table 5.18 SWOT Analysis for Herceptin, 2010 Table 5.19 Glivec/Gleevec Sales Information, 2009 Table 5.20 Glivec/Gleevec Approvals, 2009 Table 5.21 Glivec/Gleevec World Sales, 2005-2009 Table 5.22 Glivec/Gleevec World Sales Forecast, 2010-2025 Table 5.23 SWOT Analysis for Glivec/Gleevec, 2010 Table 5.24 Taxotere Sales Information, 2009 Table 5.25 Taxotere Approvals, 2009 Table 5.26 Taxotere World Sales, 2005-2009 Table 5.27 Taxotere World Sales Forecast, 2010-2025 Table 5.28 SWOT Analysis for Taxotere, 2010 Table 5.29 Eloxatin Sales Information, 2009 Table 5.30 Eloxatin World Sales, 2005-2009 Table 5.31 Eloxatin World Sales Forecast, 2010-2025 Table 5.32 SWOT Analysis for Eloxatin, 2010 Table 5.33 Arimidex Sales Information, 2009 Table 5.34 Arimidex World Sales, 2005-2009 Table 5.35 Arimidex World Sales Forecast, 2010-2025 Table 5.36 SWOT Analysis for Arimidex, 2010 Table 5.37 Gemzar Sales Information, 2009 Table 5.38 Gemzar Approvals, 2009 Table 5.39 Potential Indications for Gemzar, 2009 Table 5.40 Gemzar World Sales, 2005-2009 Table 5.41 Gemzar World Sales Forecast, 2010-2025 Table 5.42 SWOT Analysis for Gemzar, 2010 Table 5.43 Erbitux Sales Information, 2009 Table 5.44 Marketing of Erbitux: Revenue Split, 2009 Table 5.45 Erbitux Approvals, 2009 Table 5.46 Potential Indications for Erbitux, 2009 Table 5.47 Erbitux World Sales, 2005-2009 Table 5.48 Erbitux World Sales Forecast, 2010-2025 Table 5.49 SWOT Analysis for Erbitux, 2010 Table 5.50 Alimta Sales Information, 2009 Table 5.51 Alimta Approvals, 2009 Table 5.52 Potential Indications for Alimta, 2009 Table 5.53 Alimta World Sales, 2005-2009 Table 5.54 Alimta World Sales Forecast, 2010-2025 Table 5.55 SWOT Analysis for Alimta, 2010 Table 6.1 The Top Five Oncology Companies: Relevant World Sales, 2009 Table 6.2 Roche’s Oncology Revenue, 2009 Table 6.3 Key Products in Roche’s Oncology Portfolio: World Sales, 2009 Table 6.4 Roche’s Oncology Pipeline, 2009 Table 6.5 Novartis’ Oncology Revenue, 2009 Table 6.6 Key Products in Novartis’ Oncology Portfolio: World Sales, 2009 Table 6.7 Novartis’ Oncology Pipeline, 2009 Table 6.8 Sanofi-Aventis’ Oncology Revenue, 2009 Table 6.9 Key Products in Sanofi-Aventis’ Oncology Portfolio: World Sales, 2009 Table 6.10 Sanofi-Aventis’ Oncology Pipeline, 2009 Table 6.11 AstraZeneca’s Oncology Revenue, 2009 Table 6.12 Key Products in AstraZeneca’s Oncology Portfolio: World Sales, 2009 Table 6.13 AstraZeneca’s Oncology Pipeline, 2009 Table 6.14 Eli Lilly’s Oncology Revenue, 2009 Table 6.15 Key Products in Eli Lilly’s Oncology Portfolio: World Sales, 2009 Table 6.16 Eli Lilly’s Oncology Pipeline, 2009 Table 7.1 SWOT Analysis of the Global Anti-Cancer Drugs Market, 2010-2025 Table 7.2 The Importance of Personalised Medicine in Oncology Table 7.3 Disadvantages of Intravenous Chemotherapy Table 7.4 Disadvantages of Oral Administration Table 7.5 How the NCI Allocated its Cancer Research Budget in 2008 Table 7.6 Estimated GDP per Capita for BRICT and the US, 2010-2025 Figure 2.1 Global Cancer Incidence and Mortality, 2010-2025 Figure 2.2 The Ten Most Common Cancers by Incidence, 2008 Figure 2.3 Five-Year Survival Rates of Nine Cancers in the UK Figure 4.1 Oncology Drug Sales by Region, 2009 Figure 4.2 Oncology Market Shares of the Seven Major Markets and Five Emerging Markets, 2009 Figure 4.3 Comparison of the Oncology Revenues of the US, Six Other Leading Markets and Five Emerging Market Groups, 2009 Figure 4.4 The Seven Leading National Markets: Market Shares, 2009 Figure 4.5 The Five Emerging Markets: Market Shares, 2009 Figure 4.6 Oncology Market by Therapy Type: Market Shares, 2009 Figure 4.7 Oncology Drug Market: World Sales Forecasts, 2010-2025 Figure 4.8 Traditional Antineoplastics: World Sales and Market Shares, 2009 Figure 4.9 Traditional Antineoplastics Market: World Sales Forecast, 2010-2025 Figure 4.10 Novel Antineoplastics Market Categories: Market Shares, 2009 Figure 4.11 Novel Antineoplastics Market: World Sales Forecast, 2010-2025 Figure 4.12 Hormone Therapy Subtypes: World Sales and Market Shares, 2009 Figure 4.13 Hormone Therapy Market: World Sales Forecast, 2010-2025 Figure 4.14 Immunotherapy Subtypes: Market Shares, 2009 Figure 4.15 Immunotherapy Market: World Sales Forecast, 2010-2025 Figure 4.16 Overall Categories: Market Shares, 2010-2025 Figure 5.1 Top Ten Drugs by Category and Subcategory, 2009 Figure 5.2 Costs of the Top Ten Anti-Cancer Drugs in the UK, 2009 Figure 5.3 Avastin World Sales Forecast, 2010-2025 Figure 5.4 MabThera World Sales Forecast, 2010-2025 Figure 5.5 Herceptin World Sales Forecast, 2010-2025 Figure 5.6 Glivec/Gleevec World Sales Forecast, 2010-2025 Figure 5.7 Taxotere World Sales Forecast, 2010-2025 Figure 5.8 Eloxatin World Sales Forecast, 2010-2025 Figure 5.9 Arimidex World Sales Forecast, 2010-2025 Figure 5.10 Gemzar World Sales Forecast, 2010-2025 Figure 5.11 Marketing of Erbitux: Revenue Split, 2009 Figure 5.12 Erbitux World Sales Forecast, 2010-2025 Figure 5.13 Alimta World Sales Forecast, 2010-2025 Figure 6.1 Top Five Companies: Relevant Market Shares, 2009 Figure 6.2 How Oncology Products Contributed to Roche’s Pharmaceutical Revenue, 2009 Figure 6.3 Key Products in Roche’s Oncology Portfolio by Share of Oncology Revenue, 2009 Figure 6.4 How Oncology Products Contributed to Novartis’ Pharmaceutical Revenue, 2009 Figure 6.5 Key Products Novartis’ Oncology Portfolio by Share of Oncology Revenues, 2009 Figure 6.6 How Oncology Products Contributed to Sanofi-Aventis’ Pharmaceutical Revenue, 2009 Figure 6.7 Key Products in Sanofi-Aventis’ Oncology Portfolio by Share of Oncology Revenue, 2009 Figure 6.8 How Oncology Products Contributed to AstraZeneca’s Pharmaceutical Revenue, 2009 Figure 6.9 Key Products in AstraZeneca’s Oncology Portfolio by Share of Oncology Revenue, 2009 Figure 6.10 How Oncology Products Contributed to Eli Lilly’s Pharmaceutical Revenue, 2009 Figure 6.11 Key Products in Eli Lilly’s Oncology Portfolio by Share of Oncology Revenue, 2009 Figure 7.1 NCI Research Spend, Incidence and Mortality for Different Cancers [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
